Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

BACKGROUND: A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen d...

Descripción completa

Detalles Bibliográficos
Autores principales: Merseburger, Axel S., Hammerer, Peter, Rozet, Francois, Roumeguère, Thierry, Caffo, Orazio, da Silva, Fernando Calais, Alcaraz, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512260/
https://www.ncbi.nlm.nih.gov/pubmed/25261259
http://dx.doi.org/10.1007/s00345-014-1406-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512260/
https://www.ncbi.nlm.nih.gov/pubmed/25261259
http://dx.doi.org/10.1007/s00345-014-1406-2

Ejemplares similares